NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it
Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall
Roche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, as the Swiss pharma attempts to breathe new life into the drug curren
